Biogen (NASDAQ: BIIB) has recently received a number of price target changes and ratings updates:

  • 10/2/2017 – Biogen had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $319.00 price target on the stock. They wrote, “We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x.””
  • 9/21/2017 – Biogen was downgraded by analysts at Raymond James Financial, Inc. from a “strong-buy” rating to a “market perform” rating. They now have a $319.00 price target on the stock, up previously from $244.28.
  • 9/20/2017 – Biogen is now covered by analysts at SunTrust Banks, Inc.. They set a “buy” rating and a $360.00 price target on the stock.
  • 9/14/2017 – Biogen is now covered by analysts at Royal Bank Of Canada. They set a “sector perform” rating and a $319.00 price target on the stock.
  • 9/13/2017 – Biogen had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $319.00 price target on the stock, up previously from $274.00.
  • 9/13/2017 – Biogen had its price target raised by analysts at BMO Capital Markets from $328.00 to $377.00. They now have a “market perform” rating on the stock.
  • 9/7/2017 – Biogen was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $346.83 price target on the stock.
  • 9/4/2017 – Biogen was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $316.82 price target on the stock.
  • 9/1/2017 – Biogen was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/29/2017 – Biogen was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $319.53 price target on the stock.
  • 8/25/2017 – Biogen had its “hold” rating reaffirmed by analysts at Robert W. Baird. They now have a $290.00 price target on the stock.
  • 8/23/2017 – Biogen was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $319.53 price target on the stock.
  • 8/17/2017 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $319.53 price target on the stock.
  • 8/16/2017 – Biogen was upgraded by analysts at Goldman Sachs Group, Inc. (The) from a “buy” rating to a “conviction-buy” rating. They now have a $338.00 price target on the stock.
  • 8/10/2017 – Biogen was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $319.53 price target on the stock.
  • 8/4/2017 – Biogen was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of Biogen Inc. (BIIB) traded up 0.39% during trading on Tuesday, hitting $317.39. 816,480 shares of the stock were exchanged. The company has a market cap of $67.11 billion, a P/E ratio of 20.83 and a beta of 0.77. The firm’s 50-day moving average is $307.67 and its 200 day moving average is $280.04. Biogen Inc. has a 1-year low of $244.28 and a 1-year high of $330.00.

Biogen (NASDAQ:BIIB) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported $5.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.36 by $0.68. The company had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. Biogen’s quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.21 earnings per share. Equities analysts forecast that Biogen Inc. will post $21.51 earnings per share for the current fiscal year.

In related news, EVP Susan H. Alexander sold 4,974 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the sale, the executive vice president now owns 22,258 shares of the company’s stock, valued at $6,455,042.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Susan H. Alexander sold 7,758 shares of the stock in a transaction that occurred on Wednesday, July 19th. The stock was sold at an average price of $285.00, for a total value of $2,211,030.00. Following the sale, the executive vice president now directly owns 27,232 shares in the company, valued at approximately $7,761,120. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by company insiders.

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.